Operating out of Irvine, California, Cultivation Technologies, Inc. supports producers in the medical cannabis industry by providing technology, infrastructure, manufacturing and branding services. Cultivation Technologies, Inc.’s Chief Strategy Officer, Justin Beck, guides the organization’s operations in vital areas that support expanding research and development initiatives.Cannabis research is a rapidly-growing industry that offers interested parties a variety of professional opportunities and competitive salaries as well as the opportunity to solve scientific challenges. Although the effects of cannabis are not yet fully understood in the scientific community, researchers see the potential to learn significantly more about its potential medicinal benefits. It has already been proven to have positive effects that include relieving nausea related to cancer treatment as well as alleviating pain.Employers in the cannabis research industry are searching for scientists with experience and knowledge that can be applied in this new field. Scientists looking for opportunities in the industry may want to contact the American Chemical Society’s (ACS) Cannabis Chemistry Subdivision, which provides resources such as an online journal club, networking sessions, and a scholarship for cannabis scientists presenting their research at ACS meetings.
Headquartered in Irvine, California, Cultivation Technologies, Inc., provides infrastructure, technology, genetics, and branding to the legal medical cannabis industry. Cultivation Technologies, Inc. (CTI) was cofounded by Justin Beck, who serves as the Chief Strategy Officer and plays a leading in role in guiding the company through the highly complex cannabis industry regulatory environment.CTI announced in June 2017 its execution of an agreement to perform sponsored research within the laboratory of Dr. Daniele Piomelli at the University of California, Irvine (UCI). Conducting the research is CTI Genetics, a subsidiary of CTI, under the direction of the firm’s genetics team. The research focuses on the plant’s genetic diversity, genomics, and biology, which will aid in the development of medical grade Cannabis varieties to be used for specific therapeutic symptoms.An acknowledged authority in cannabinoid research, Dr. Piomelli has authored over 400 peer-reviewed journal articles. He is a professor of Anatomy & Neurobiology at UCI’s School of Medicine, the Louise Turner Arnold Chair in Neurosciences, and a director of UCI’s Institute for the Study of Cannabis. Dr. Piomelli counts the National Institute on Drug Abuse’s first Avant-Garde Award for Innovative Medication Development Research, which he received in 2010, among his various accolades.
